Cytochrome P450-based cancer gene therapy: current status

Bibliography

• DREICER R: Locally advanced and metastatic bladder cancer. Carr. Treat. Options Oncol (2001) 2(5):431–436.
   PubMedGoogle Scholar
• HARRIS KA, REESE DM: Treatment options in hormone-refractory prostate cancer: current and future approaches. Drugs. (2001) 61(15):2177–2192.
   PubMed Web of Science ®Google Scholar
• PLUNKETT TA, MILES DW: New biological therapies for breast cancer. Int. J. Clin. Pract. (2002) 56(4):261–266.
   PubMed Web of Science ®Google Scholar
• TIAN GG, DAWSON NA: New agents for the treatment of renal cell carcinoma. Expert Rev. Anti-Cancer Ther. (2001) 1(0546–554.
   PubMedGoogle Scholar
• WATSON SA, GILLIAM AD: G17DT-a new weapon in the therapeutic armoury for gastrointestinal malignancy. Expert Opin. Biol. The]: (2001) 1(2):309–317.
   PubMed Web of Science ®Google Scholar
• ELSHAMI AA, COOK JW, AMIN KM et al.: The effect of promoter strength in adenoviral vectors containing herpes simplexvirus thymidine kinase on cancer gene therapy in vitro and in vivo. Cancer Gene Ther. (1997) 4:213–221.
   PubMed Web of Science ®Google Scholar
• IIJIMA Y, OHNO K, IKEDA H et al: Cell-specific targeting of a thymidine kinase/ ganciclovir gene therapy system using a recombinant Sindbis virus vector. hat. J. Cancer (1999) 80:110–118.
   PubMed Web of Science ®Google Scholar
• KOYAMA F, SAWADA H, FUJII H et al.: Enzyme/prodrug gene therapy for human colon cancer cells using adenovirus-mediated transfer of the Escherichia coil cytosine deaminase gene driven by a CAG promoter associated with 5-fluorocytosine administration. J. Exp. Clin. Cancer Res. (2000) 19(1):75–80.
   PubMed Web of Science ®Google Scholar
• MCCART JA, PUHLMANN M, LEE J et al.: Complex interactions between the replicating oncolytic effect and the enzyme/ prodrug effect of vaccinia-mediated tumor regression. Gene Ther. (2000) 7(14):1217–1223.
   PubMed Web of Science ®Google Scholar
• KIEVIT E, NYATI MK, NG E et al.: Yeast cytosine deaminase improves radiosensitization and bystander effect by 5-fluorocytosine of human colorectal cancerxenografts. Cancer Res. (2000)60(23):6649–6655.
   PubMed Web of Science ®Google Scholar
• WEYEL D, SEDLACEK HH, MULLER R, BRUSSELBACH S: Secreted human beta-glucuronidase: a novel tool for gene-directed enzyme prodrug therapy. Gene Ther. (2000) 7(3):224–231.
   PubMed Web of Science ®Google Scholar
• HEINE D, MULLER R,BRUSSELBACH S: Cell surface display of a lysosomal enzyme for extracellular gene-directed enzyme prodrug therapy. Gene Titer. (2001) 8(13):1005–1010.
   Web of Science ®Google Scholar
• BRIDGEWATER JA, KNOX RJ, PITTS J, COLLINS MK, SPRINGER CJ: The bystander effect of the nitroreductase/ CB1954 enzyme/prodrug system is due to a cell-permeable metabolite. Hum. Gene Titer. (1997) 8:709–717.
   PubMed Web of Science ®Google Scholar
• FRIEDLOS F, DENNY WA, PALMER BD et al. Mustard prodrugs for activation by Escherichia coil nitroreductase in gene-directed enzyme prodrug therapy. j Med. Chem. (1997) 40:1270–1275.
   PubMed Web of Science ®Google Scholar
• GREEN NK, YOUNGS DJ,NEOPTOLEMOS JP et al.: Sensitisation of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin yfl 2,4 dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coil nitroreductase gene. Cancer Gene Their(1997) 4:229–238.
   Google Scholar
• DJEHA AH, THOMSON TA, LEUNG H: Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: a well-tolerated therapy for established solid tumors. Mol. Their(2001) 3(2):233–240.
   PubMed Web of Science ®Google Scholar
• BAKINA E, FARQUHAR D: Intensely cytotoxic anthracycline prodrugs: galactosides. Anti-Cancer Drug Des. (1999) 14(6):507–515.
   PubMedGoogle Scholar
• HAMSTRA DA, REHEMTULLA A: Toward an enzyme/prodrug strategy for cancer gene therapy: endogenous activation of carboxypeptidase A mutants by the PACE/Furin family of propeptidases. Hum Gene The]: (1999) 10(2):235–248.
   PubMed Web of Science ®Google Scholar
• MARAIS R, SPOONER RA, LIGHT Y, MARTIN J, SPRINGER CJ: Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination. Cancer Res. (1996) 56(20):4735–4742.
   PubMed Web of Science ®Google Scholar
• STRIBBLING SM, FRIEDLOS F, MARTIN J et al.: Regressions of established breast carcinoma xenografts by carboxypeptidase G2 suicide gene therapy and the prodrug CMDA are due to a bystander effect. Hum. Gene Thec (2000) 11(2):285–292.
   PubMed Web of Science ®Google Scholar
• EVRARD A, CUQ P, CICCOLINI J, VIAN L, CANO JP: Increased cytotoxicity and bystander effect of 5-fluorouracil and 5-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase. Br. J. Cancer. (1999) 80(11):1726–1733.
   PubMed Web of Science ®Google Scholar
• DANKS MK, MORTON CL, KRULL EJ et al.: Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy. Clin. Cancer Res. (1999) 5(4):917–924.
   PubMed Web of Science ®Google Scholar
• MECK MM, WIERDL M, WAGNER LM: A virus-directed enzyme prodrug therapy approach to purging neuroblastoma cells from hematopoietic cells using adenovirus encoding rabbit carboxylesterase and CPT-11. Cancer Res. (2001) 61:5083–5089.
   PubMed Web of Science ®Google Scholar
• SENTER PD, BEAM KS, MIXAN B, WAHL AF: Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancerdrug. Bioconjug. Chem. (2001)12(6):1074–1080.
   PubMed Web of Science ®Google Scholar
• MARTINIELLO-WILKS R, GARCIA-ARAGON J, DAJA MM et al: In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors. Hum. Gene The]: (1998) 9(11):1617–1626.
   PubMed Web of Science ®Google Scholar
• MIKI K, XU M, GUPTA A et al: Methioninase cancer gene therapy with selenomethionine as suicide prodrug substrate. Cancer Res. (2001) 61(18):6805–6810.
   PubMed Web of Science ®Google Scholar
• SIMONOVA M, WALL A, WEISSLEDER R, BOGDANOV A JR: Tyrosinase mutants are capable of prodrug activation in transfected nonmelanotic cells.Cancer Res. (2000) 60(23):6656–6662.
   PubMed Web of Science ®Google Scholar
• GRECO 0, FOLKES LK, WARDMANP, TOZER GM, DACHS GU: Development of a novel enzyme/prodrug combination for gene therapy of cancer: horseradish peroxidase/indole-3-acetic acid. Cancer Gene Ther. (2000) 7(11):1414–1420.
   PubMed Web of Science ®Google Scholar
• CHEN L, WAXMAN DJ: Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P450 gene transfer: development of a combined chemotherapy/ cancer gene therapy strategy. Cancer Res.(1995) 55:581–589.
   PubMed Web of Science ®Google Scholar
• MANOME Y, WEN PY, CHEN L et al: Gene therapy for malignant gliomas using replication incompetent retroviral and adenoviral vectors encoding the cytochrome P450 2B1 gene together with cyclophosphamide. Gene The]: (1996) 3:513–520.
   PubMed Web of Science ®Google Scholar
• WEI MX, TAMIYA T, CHASE M et al: Experimental tumor therapy in mice using the cyclophosphamide- activating cytochrome P450 2B1 gene. Hum. Gene The]: (1994) 5:969–978.
   Google Scholar
• WEI MX, TAMIYA T, CHASE M et al: Diffusible cytotoxic metabolites contribute to the M vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm. Gin. Cancer Res. (1995) 1:1171–1177.
   Web of Science ®Google Scholar
• AGHI M, CHOU TC, SULING K et al.: Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res(1999) 59:3861–3865.
   PubMed Web of Science ®Google Scholar
• CHASE M, CHUNG RY, CHIOCCA EA: An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat. Biotechnol. (1998) 16:444–448.
   PubMed Web of Science ®Google Scholar
• ••A genetically modified HSV-1 vector wasshown to have oncolytic activity and was used to enhance CYP2B1/CPA GDEPT.
   Google Scholar
• CHEN L, WAXMAN DJ, CHEN, KUFE DW: Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. Cancer Res. (1996) 56:1331–1340.
   PubMed Web of Science ®Google Scholar
• ICHIKAWA T, PETROS WP,LUDEMAN SM: Intraneoplastic polymer-based delivery of cyclophosphamide for intratumoral bioconversion by a replicating oncolytic viral vector. Cancer Res. (2001) 61:864–868.
   PubMed Web of Science ®Google Scholar
• LOHR M, MULLER P, KARLE P et al.: Targeted chemotherapy by intratumour injection of encapsulated cells engineered to produce CYP2B1, an ifosfamide activating cytochrome P450. Gene The]: (1998) 5:1070–1078.
   PubMed Web of Science ®Google Scholar
• •A treatment strategy for pancreatic cancer using cellulose sulphate encapsulated cells that express CYP2B1 enzyme implanted into pre-established tumour xenografts followed by IFA treatment.
   Google Scholar
• LOHR M, BAGO ZT, BERGMEISTER H et al.: Cell therapy using microencapsulated 293 cells transfected with a gene construct expressing CYP2B1, an ifosfamide converting enzyme, instilled intra-arterially in patients with advanced-stage pancreatic carcinoma: a Phase I/II study. J. Mol. Med. (1999) 77(4):393–398.
   PubMed Web of Science ®Google Scholar
• •This paper describes the clinical protocol of a Phase I/II pancreatic cancer trial using encapsulated cells expressing CYP2B1 delivered by supraselective angiography to the tumour vasculature followed by IFA treatment.
   Google Scholar
• KARLE P, RENNER M, SALMONS B, GUNZBURG WH: Necrotic, rather than apoptotic, cell death caused by cytochrome P450-activated ifosfamide. Cancer Gene Thec (2001) 8(3):220–230.
   PubMed Web of Science ®Google Scholar
• KARLE P, MULLER P, RENZ R et al.: Intratumoral injection of encapsulated cells producing an oxazaphosphorine activating cytochrome P450 for targeted chemotherapy. Adv. Exp. Med. Biol. (1998) 451:97–106.
   PubMed Web of Science ®Google Scholar
• THATCHER NJ, EDWARDS RJ, LEMOINE NR, DOEHMER J, DAVIES DS: The potential of acetaminophen as a prodrug in gene-directed enzyme prodrug therapy. Cancer Gene Ther. (2000) 7(4):521–525.
   PubMed Web of Science ®Google Scholar
• KAN 0, GRIFFITHS L, BABAN D et Direct retroviral delivery of human cytochrome P450 2B6 for gene-directed enzyme prodrug therapy of cancer. Cancer Gene Ther. (2001) 8(7):473–482.
   PubMed Web of Science ®Google Scholar
• ••In vitro and in vivo efficacy of CYP2B6/CPA GDEPT was shown by direct injection of vector expressing CYP2B6 into tumour xenografts followed by treatment with CPA.
   Google Scholar
• JOUNAIDI Y, WAXMAN DJ: Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy. Cancer Res. (2000) 60:3761–3769.
   PubMed Web of Science ®Google Scholar
• ••Using 9L glioma cells as a model, thispaper showed enhanced in vitro and in vivo efficacy of using CPA and tirapazarnine together as compared to using CPA alone with CYP2B6+P450R for cancer treatment.
   Google Scholar
• JOUNAIDI Y, WAXMAN DJ: Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P450/cytochrome P450 reductase-based cancer gene therapy. Cancer Res. (2001) 61(11):4437–4444.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ PS, WAXMAN DJ: Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumour cells. Mol Pharmacol. (2001) 60(6):1268–1279.
   PubMed Web of Science ®Google Scholar
• ••Results from various apoptotic pathwayactivation related assays showed that P450/ CPA mediated tumour cell death is mainly via apoptosis and this apoptotic death is abrogated by the overexpression of Bc1–2.
   Google Scholar
• JOUNAIDI Y, HECHT JE, WAXMAN DJ: Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine- based cancer gene therapy. Cancer Res. (1998) 58:4391–4401.
   PubMed Web of Science ®Google Scholar
• ••This paper has evaluated the in vitroefficacy of human cytochrome P450 2B6, 2C8, 2C9, 2C18-Met, 2C18-Thr, 2C19 and 3A4 isoforms with CPA and IFA and the in vivo efficacy of CYP2B6+P450R/ CPA or CYP2C18-Met+P450R/CPA.
   Google Scholar
• ZHOU D, LU Y, STEINER MS, DALTON JT: Cytochrome P450 2C9 sensitizes human prostate tumor cells to cyclophosphamide via a bystander effect. Antimicrob. Agents Chemother (2000)44(10):2659–2663.
   PubMed Web of Science ®Google Scholar
• RAINOV NG, DOBBERSTEIN KU, SENA-ESTEVES M et al.: New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol. Hum. Gene Ther. (1998) 9(9):1261–1273.
   PubMed Web of Science ®Google Scholar
• CHEN L, WAXMAN DJ: Cytochrome P450 Gene-directed enzyme prodrug therapy (GDEPT) for Cancer. Carr. Pharm. Des. (2002) 8(15):1405–1416.
   PubMed Web of Science ®Google Scholar
• ••This review discuss various aspects ofP450-based GDEPT to date.
   Google Scholar
• VILE RG, NELSON JA, CASTLEDEN S, CHONG H, HART IR: Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res. (1994) 54(23):6228–6234.
   PubMed Web of Science ®Google Scholar
• WAXMAN DJ, CHEN L, HECHT JE, JOUNAIDI Y: Cytochrome P450-based cancer gene therapy: recent advances and future prospects. Drug Metab. Rev (1999) 31(2):503–522.
   PubMed Web of Science ®Google Scholar
• •This review discuss the advances of P450-based GDEPT to the year 1998.
   Google Scholar
• LOHR M, HOFFMEYER A, KROGER Jet al.: Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. Lancet. (2001) 357(9268):1591–1592.
   Google Scholar
• ••This paper showed the results of a Phase I-II clinical trial in pancreatic cancer patients to assess the safety of local activation of IFA and encapsulated allogeneic cells expressing CYP2B1 delivered by supraselective angiography to the tumour vasculature.
   Google Scholar
• MAZARAKIS ND, AZZOUZ M, ROHLL JB et al.: Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. Hum. MoL Genet. (2001) 10(19):2109–2121.
   PubMed Web of Science ®Google Scholar
• ROHLL JB, MITROPHANOUS KA, MARTIN-RENDON E et al: Design, production, safety, evaluation, and clinical applications of nonprimate lentiviral vectors. Methods Enzymol (2002) 346:466–500.
   PubMed Web of Science ®Google Scholar
• •A detailed review on the potential of using non-primate lentiviral vectors including the EIAV-based Lentivector® (Oxford BioMedica) for gene therapy.
   Google Scholar
• GRIFFITHS L, BINLEY K, IQBALL S et al.: The macrophage - a novel system to deliver gene therapy to pathological hypwda. Gene Ther. (2000) 7(3):255–262.
   PubMed Web of Science ®Google Scholar
• •P450 based GDEPT in the context of cell based gene delivery.
   Google Scholar
• DACHS GU, DOUGHERTY GJ, STRATFORD IJ et al.: Targeting gene therapy to cancer: a review. Oncol Res. (1997) 9(6-7):313–325.
   PubMed Web of Science ®Google Scholar
• •Hypoxia response elements (HRE) derived from the oxygen-regulated phosphoglycerate kinase gene were utilised to control gene expression in human tumour cells in vitro and in experimental tumours.
   Google Scholar
• DACHS GU, PATTERSON AV, FIRTH JD et al: Targeting gene expression to hypoxic tumor cells. Nat. Med (1997)3(5):515–520.
   PubMed Web of Science ®Google Scholar
• ••Their results demonstrated that gene expression controlled by the HRE promoter is active in hypoxic tumour cells.
   Google Scholar
• BOAST K, BINLEY K, IQBALL S et al: Characterization of physiologically regulated vectors for the treatment of ischemic disease. Hum. Gene Ther. (1999) 10(13):2197–2208.
   PubMed Web of Science ®Google Scholar
• ••This paper demonstrates the developmentof an optimised hypoxia responsive promoter system.
   Google Scholar
• YU LJ, MATIAS J, SCUDIERO DA et al.: P450 enzyme expression patterns in the NCI human tumour cell line panel. Drug Metab. Dispos. (2001) 29(3):304–312.
   PubMed Web of Science ®Google Scholar
• ••This paper has a detailed profile of theactivities of 11 human P450 isoforms and P450R in 60 human tumour cell lines of leukaemia, brain tumour, breast cancer, colon cancer, lung cancer, melanoma, ovarian cancer, prostate cancer and renal cancer origins. However, the currently available assays for the measurement of P450 activities used here are still unable to link the activity to a single P450 isoform.
   Google Scholar
• CHANG TK, WEBER GE CRESPI CL, WAXMAN DJ: Differential activation of cyclophosphamide and ifosfamide by cytochromes P450 2B and 3A in human liver microsomes. Cancer Res. (1993)53(23):5629–5637.
   PubMed Web of Science ®Google Scholar
• ROY P, TRETYAKOV 0, WRIGHT J, WAXMAN DJ: Stereoselective metabolism of ifosfamide by human P450s 3A4 and 2B6. Favorable metabolic properties of R-enantiomer. Drug Metab. Dispos. (1999) 27(11):1309–1318.
   PubMed Web of Science ®Google Scholar
• HUANG Z, ROY P, WAXMAN DJ: Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamideand ifosfamide. Biechem. Phannacel. (2000) 59(8):961–972.
   PubMed Web of Science ®Google Scholar
• CHANG TK, YU L, GOLDSTEIN JA, WAXMAN DJ: Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Phannacegenetics. (1997) 7(3):211–221.
   PubMedGoogle Scholar
• HUANG Z, WAXMAN DJ: Modulation of cyclophosphamide-based cytochrome P450 gene therapy using liver P450 inhibitors. Cancer Gene Ther. (2001) 8(6):450–458.
   PubMed Web of Science ®Google Scholar